Quantcast
Home > Quotes > PTCT
PTCT

PTC Therapeutics, Inc. Common Stock (PTCT) Quote & Summary Data

$34.52
*  
1.16
3.48%
Get PTCT Alerts
*Delayed - data as of Dec. 10, 2018  -  Find a broker to begin trading PTCT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    PTCT After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 27 / $ 45.99
1 Year Target
46.5
Today's High / Low
$ 34.55 / $ 32.86
Share Volume
533,994
50 Day Avg. Daily Volume
793,657
Previous Close
$ 33.36
52 Week High / Low
$ 52.95 / $ 15.60
Market Cap
1,741,700,870
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.70
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.86

Intraday Chart

Shares Traded

Share Volume:
533,994
50 Day Avg. Daily Volume:
793,657

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.70

Trading Range

The current last sale of $34.52 is 121.28% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 34.55 $ 52.95
 Low: $ 32.86 $ 15.60

ETFs with PTCT as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
3.62% Invesco DWA Healthcare Momentum ETF (PTH) -16.20 (-17.32%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a science-led global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. We have launched two rare disease products and have a global commercial footprint. Our recent ability to commercialize products is the foundation that drives our continued investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. Our Strategy Our strategy is to bring best in-class therapies with differentiated clinical benefit to patients affected by rare disorders, by leveraging our global commercial infrastructure to maximize value for our patients and stakeholders.  ... More ...  


Risk Grade

Where does PTCT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 33.14
Open Date:
Dec. 10, 2018
Close Price:
$ 34.52
Close Date:
Dec. 10, 2018

Consensus Recommendation

Analyst Info